SCHEMBL4226773

SCHEMBL4226773

CCC(CC)NC(=O)Nc1cc(F)c(Oc2ccc(C(N)=O)cc2)cc1F

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PKM P14618 2/20 0.52
TAS1R3 Q7RTX0 3/20 0.49
TAS1R1 Q7RTX1 3/20 0.49
PARP10 Q53GL7 4/20 0.44
POLB P06746 2/20 0.40
MAPK1 P28482 1/20 0.40
S1PR2 O95136 2/20 0.39
ALDH1A1 P00352 1/20 0.38
KMT2A Q03164 1/20 0.38
PARP15 Q460N3 1/20 0.38
PARP14 Q460N5 1/20 0.38
PARP16 Q8N5Y8 1/20 0.38
PARP11 Q9NR21 1/20 0.38
PARP4 Q9UKK3 1/20 0.38
HSD17B10 Q99714 1/20 0.37
OPRM1 P35372 1/20 0.36
OPRD1 P41143 1/20 0.36
OPRK1 P41145 1/20 0.36
SLC6A2 P23975 1/20 0.36
SLC6A4 P31645 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4237834 0.91 TAS1R3 (0.55) PKMTAS1R3TAS1R1PARP10POLB
SCHEMBL4226776 0.89 PKM (0.54) PKMTAS1R3TAS1R1POLBMAPK1
SCHEMBL4744778 0.85 PKM (0.52) PKMTAS1R3TAS1R1POLBMAPK1
SCHEMBL4228409 0.82 PKM (0.45) PKMTAS1R3TAS1R1POLBMAPK1
SCHEMBL4687220 0.82 EPHX2 (0.49) PARP10POLBALDH1A1
SCHEMBL4234355 0.80 TAS1R3 (0.57) PKMTAS1R3TAS1R1POLBMAPK1
SCHEMBL4229012 0.79 PKM (0.50) PKMTAS1R3TAS1R1POLBMAPK1
SCHEMBL4236704 0.78 PKM (0.66) PKMTAS1R3TAS1R1PARP10POLB
SCHEMBL4687897 0.77 MCHR1 (0.36) POLBS1PR2KMT2AOPRM1OPRD1
SCHEMBL4235502 0.77 TAS1R3 (0.40) PKMTAS1R3TAS1R1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090233910-A1 Npy antagonists, preparation and uses CEREP (FR) 2009-09-17 US claimed
EP-1879887-A2 NPY ANTAGONISTS, PREPARATION AND USE Cerep (FR) 2008-01-23 EP claimed
WO-2006108965-A2 NPY ANTAGONISTS, PREPARATION AND USE CEREP (FR) 2006-10-19 WO claimed
US-20090233910-A1 Npy antagonists, preparation and uses CEREP (FR) 2009-09-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090233910-A1 Npy antagonists, preparation and uses NPY1R, NPY5R, NPY2R PKM 1734/4885TAS1R3 1436/4885TAS1R1 1073/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.